14 results
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
8 Sep 23
Regulation FD Disclosure
7:04am
at least one event of Investigator- reported DS Range of Initial Onset: 4 to 42 days EXPERT ADJUDICATION COMMITTEE ASSESSMENT OF DIFFERENTIATION
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
8 Aug 23
Foghorn Therapeutics Announces Chief Medical Officer Succession
7:05am
experience and expertise in oncology and as a leukemia expert will be integral to our plans as we continue to advance our pipeline and develop medicines
8-K
EX-99.2
FHTX
Foghorn Therapeutics Inc
4 Aug 23
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
7:05am
of Initial Onset: 4 to 42 days EXPERT ADJUDICATION COMMITTEE ASSESSMENT OF DIFFERENTIATION SYNDROME Potential DS Symptom include: Pleural effusion
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
28 Jun 23
Regulation FD Disclosure
7:05am
of Initial Onset: 4 to 42 days EXPERT ADJUDICATION COMMITTEE ASSESSMENT OF DIFFERENTIATION SYNDROME Potential DS Symptom include: Pleural effusion
8-K
EX-99.1
ps0dg 82km
5 Jun 23
Regulation FD Disclosure
7:02am
8-K
EX-3.2
okomh1e 2qkbdlc
27 Oct 20
Amendments to Articles of Incorporation or Bylaws
5:00pm
S-1/A
EX-3.5
b9nn xe0os0h3am349q2
19 Oct 20
IPO registration (amended)
6:06am
S-1
EX-10.8
1e3s1
2 Oct 20
IPO registration
4:03pm
DRS
rl65qhq
28 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next